Molecular markers in glioma

Journal of Neuro-Oncology

Volumn 134, Issue 3, 2017, Pages 505-512

  Ludwig, Kirsten ^a,b   Kornblum, Harley I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; Glioma stem cell; Molecular markers; Mutations; Pathways

Indexed keywords

ABC TRANSPORTER; BMI1 PROTEIN; CD133 ANTIGEN; CD15 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; ISOCITRATE DEHYDROGENASE; KRUPPEL LIKE FACTOR 4; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYC PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEASOME; PROTEIN P53; RAF PROTEIN; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; VASCULOTROPIN;

ASTROCYTOMA; CANCER STAGING; CARCINOGENESIS; CATALYSIS; CELLULAR DISTRIBUTION; CHROMOSOME 19Q; CHROMOSOME 1P; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; NONHUMAN; OLIGODENDROGLIOMA; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SEQUENCE HOMOLOGY; ANIMAL; BRAIN TUMOR; CANCER STEM CELL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASTIC STEM CELLS;

EID: 85013668842     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-017-2379-y     Document Type: Review

References (65)

1. Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
2. Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173
3. Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
4. Freije WA et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18):6503–6510
5. Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
6. McNamara MG, Sahebjam S, Mason WP (2013) Emerging biomarkers in glioblastoma. Cancers 5(3):1103–1119
7. Alentorn A et al (2015) Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther 15(8):955–962
8. Cohen AL, Colman H (2015) Glioma biology and molecular markers. Cancer Treat Res 163:15–30
9. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62(15):4364–4368
10. Patel M et al (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21(9):1247–1266
11. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
12. Gupta K, Salunke P (2012) Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 138(12):1971–1981
13. Nakagawachi T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22(55):8835–8844
14. Riemenschneider MJ et al (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120(5):567–584
15. Horbinski C et al (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14(6):777–789
16. Ichimura K et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347
17. Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
18. Balss J et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602
19. Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67(1):1–15
20. Sugawa N et al (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87(21):8602–8606
21. Nathanson DA et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166):72–76
22. Karsy M et al (2015) A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 38(3):E4
23. Mao H et al (2012) Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Investig 30(1):48–56
24. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21–35
25. Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135(5):558–568
26. Lam PY et al (2000) Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 14(1):28–32
27. Cancer Genome Atlas Research (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068
28. Aldape K et al (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848
29. Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467–470
30. Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405
31. Jones DT et al (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28(20):2119–2123
32. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10:128
33. Cho DY et al (2013) Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 22(4):731–739
34. Seymour T, Nowak A, Kakulas F (2015) Targeting aggressive cancer stem cells in glioblastoma. Front Oncol 5:159
35. Lathia JD et al (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217
36. Hemmati HD et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100(25):15178–15183
37. Bradshaw A et al (2016) Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg 3:21
38. Trepant AL et al (2015) Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. Tumor Biol 36(3):1943–1953
39. Dahlrot RH et al (2013) What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 6(3):334–348
40. Bao S et al (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 68(15):6043–6048
41. Yanagisawa M (2011) Stem cell glycolipids. Neurochem Res 36(9):1623–1635
42. Lagadec C et al (2014) The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells 32(1):135–144
43. Lathia JD et al (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5):421–432
44. Shmelkov SV et al (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37(4):715–719
45. Schmohl JU, Vallera DA, CD133, selectively targeting the root of cancer. Toxins, 2016. 8(6)
46. Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828
47. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401
48. Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5(6):563–581
49. Xia CL et al (2003) A2B5 lineages of human astrocytic tumors and their recurrence. Int J Oncol 23(2):353–361
50. Auvergne RM et al (2013) Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3(6):2127–2141
51. Chen J et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522–526
52. Lendahl U, Zimmerman LB, McKay RD (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585–595
53. Xie L et al (2015) Characterization of nestin, a selective marker for bone marrow derived mesenchymal stem cells. Stem Cells Int 2015:762098
54. Kastan MB et al (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75(10):1947–1950
55. Storms RW et al (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96(16):9118–9123
56. Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1):17–25
57. Munakata K et al., Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clin Cancer Res, 2016
58. Vlashi E et al (2009) In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101(5):350–359
59. Lagadec C et al (2014) Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer 14:152
60. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45(8):872–877
61. Szakacs G et al (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234
62. Bleau AM et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3):226–235
63. Hambardzumyan D, Squatrito M, Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10(6):454–456
64. Deleyrolle LP et al (2011) Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134(Pt 5):1331–1343
65. Zeng L et al (2016) Label-retaining assay enriches tumor-initiating cells in glioblastoma spheres cultivated in serum-free medium. Oncol Lett 12(2):815–824